Biocon Biologics gets credit boost from S&P, outlook stable

The rating on senior secured notes issued by Biocon Biologics Global PLC was also upgraded to ‘BB+.’

Shionogi boosts stake in ViiV Healthcare in $2.125 billion deal, Pfizer exits

Under the deal, ViiV Healthcare will issue new shares to Shionogi for $2.125 billion and cancel Pfizer’s holding

JB Pharma Q3 FY26 PAT up by 22% to Rs. 198 Cr

The company recorded revenue of Rs. 1,065 crore in the third quarter of FY26

Boston Scientific to acquire Penumbra in $14.5 billion deal

Penumbra projects fourth-quarter revenue growth of 21.4% to 22.0%, with full-year 2025 revenue expected to reach approximately $1.4 billion

Remedium Lifecare posts consolidated Q2 FY26 net profit higher at Rs. 8.62 Cr

Consolidated revenue from operations stood at Rs. 111.05 crore

Merck KGaA Q3 2025 net sales remains flat amid geopolitical uncertainty

Novo Nordisk’s new CEO doubles down on obesity, diabetes push despite mixed Q3

Sales from Novo’s GLP-1 portfolio—including Wegovy for obesity and Ozempic for type 2 diabetes reached $5.6 billion

Amgen confident in US biosimilar market’s strength as sales surge 52%

Philips reiterates FY25 outlook following steady Q3 performance

Adjusted EBITDA increased by 12.3 per cent to $531 million, up from $516 million in the same period last year

Teva reports 11th consecutive quarter of growth

Teva reported third quarter revenues of $4.5 billion, an increase of 3 per cent year-over-year.